News
In a competitive job market, how applicants present themselves in interviews is critical. Asking about promotions and expressing dislike for the work theyâd be doing are just a few reasons hiring managers donât extend job offers.
FEATURED STORIES
PitchBookâs 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressedâand thereâs more to come in 2026.
Regulatory uncertainty is no longer background noise. It is a material investment risk that reshapes how capital is deployed and pipelines are prioritized.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The FDAâs refusal to review Modernaâs mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, uniQure and many more.
THE LATEST
Altimmuneâs obesity candidate pemvidutide strongly preserved lean muscle mass, with fat accounting for more than 78% of weight lost by participants in a Phase II study.
Novo Nordiskâs Wegovy elicited greater weight loss in women than in men with heart failure, according to data presented Sunday at the American Diabetes Associationâs 2024 Scientific Sessions.
The combined company began trading Friday under the Nasdaq symbol TECX. A $130 million private placement was also completed, with a cash runway into mid-2027.
Jazz Pharmaceuticalsâ calcium channel modulator suvecaltamide in a mid-stage trial was unable to significantly lower tremor burden in patients with essential tremor, the company reported Thursday.
Vertex Pharmaceuticalsâ three cystic fibrosis drugsâKaftrio/Trikafta, Symkevi and Orkambiâwill now be available through Englandâs National Health Service, following the signing of a long-term reimbursement agreement.
Vanda Pharmaceuticals has rejected two unsolicited takeover offers, saying that they are âopportunistic attemptsâ to acquire the biotech at a heavily discounted price.
While Thursdayâs label expansion and traditional approval for the gene therapy is an important milestone, many challenges still face the Duchenne muscular dystrophy community.
Zealand Pharmaâs petrelintide cut body weight by more than 8% on average, with a good overall safety and tolerability profile.
On the heels of a Phase III flop for Pfizerâs Duchenne muscular dystrophy gene therapy candidate, the FDA has green lighted the expanded use of Sarepta Therapeuticsâ Elevidys.
The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Here are some strategies company are employing to manage the drop in revenue.